Chantale Bernatchez, Ph.D., is Head of Process Development at CTMC. With more than 20 years of experience in the fields of immunology and T-cell therapy, Dr. Bernatchez has been instrumental in advancing academic and biotechnology work in TIL (tumor-infiltrating lymphocytes) and CAR-T (chimeric antigen receptor T-cells) biology, process development, and manufacturing. Dr. Bernatchez leads CTMC’s Process Development team of 12 scientists and associates who are developing the latest applications of CAR T and TILs as therapies for cancer. Prior to her role with CTMC, she was Associate Director, Cell Therapy Process Development at MD Anderson Cancer Center. She holds four patents on TIL/adoptive cell therapy.
Chantale Bernatchez, PhD
